RxDoctor Payments Data

Christina Muzny

Infectious Disease · Birmingham, ALNPI 1366547473

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Cepheid at 36.5% of the total. Among infectious disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$111,274in general payments, 2019–2025

Across 117 payments — averaging $951.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cepheid$41K
  • Merck$26K
  • Abbott$18K
  • Roche Diagnostics Corporation$7K
  • BD$5K
  • Scynexis, Inc.$5K
  • plus $9K from 7 others
$780,549in research payments, 2019–2025

Across 67 payments — averaging $11,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$666K
  • Biontech SE$74K
  • Lupin Inc.$34K
  • Ortho-clinical Diagnostics, Inc.$7K

What the payments were for

  • Consulting fees$57,56652%
  • Speaking & faculty fees$40,38536%
  • Travel & lodging$10,0209%
  • Food & beverage$3,3033%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$111,274 in reported general payments places this provider in the 95th percentile of 104 infectious disease providers in Alabama.

See all infectious disease providers in Alabama

Medicare billing

Part B allowed, 2024
$10,630
Medicare patients
58
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala39$143,976
PrezcobixDarunavir/Cobicistat11$25,074
Vancomycin Hcl13$1,263
ValacyclovirValacyclovir Hcl14$620
Albuterol Sulfate HfaAlbuterol Sulfate19$485
Gabapentin37$401
Rosuvastatin Calcium21$399
Lisinopril17$87
Trazodone Hcl19$76
Atorvastatin Calcium15$55
Tamsulosin Hcl11$54
Omeprazole14$38
Escitalopram Oxalate12$32
Clonazepam11$13

Paid to pharmacies, not to this prescriber.

Other infectious disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →